James Beck, PhD, on Identifying Genetic Variants of Parkinson Disease

Video

The chief scientific officer and senior vice president of the Parkinson’s Foundation discussed mutations the Parkinson’s Foundation has identified.

“What we hope to do by our initiative is not only advanced the potential for precision medicine therapies but change the standard of care for those living with Parkinson's disease.”

The Parkinson’s Foundation is aiming to increase the genetics knowledge base of people with Parkinson disease (PD) as precision medicine and gene therapies grow in prominence and are starting to be explored and tested in more fields with the launce of PDGENEration (NCT04057794).

The Foundation believes genetic counseling and testing for people with PD needs to become part of the standard of care to enable future genetic medicine treatment or participation in clinical trials. Currently, the genetic status of many patients with PD remainsunknown since most have not been genetically tested. Participation in PDGENEration is available at-home or in-person at sites across the US to people with PD.

CGTLive spoke with James Beck, PhD, chief scientific officer and senior vice president, Parkinson’s Foundation, to learn more about the findings that PDGENEration has discovered. Neurologists seeking more information about PD GENEration can visit PDGENEration.com or email [email protected] questions about enrollment.

REFERENCE
Parkinson’s Foundation announces major expansion of PD GENErationstudy, increasing access to genetic testing and counseling across the U.S. News release. Parkinson’s Foundation. May 3, 2022. https://www.parkinson.org/about-us/press-release/Parkinsons-Foundation-expansion-PD-GENEration-study
Recent Videos
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Related Content
© 2025 MJH Life Sciences

All rights reserved.